While both EGFR and HER2 are excellent targets and a number of targeted therapies have been successfully transformed to the clinic for patients with EGFR- or HER2-mutated NSCLC, there is no Food and Drug Administration (FDA)-approved HER3-targeted therapy for cancer treatment. Here, ERBB3 is linked to non-small cell lung carcinoma.